PATENT CLAIM ANALYSIS

Application Number: 16016053
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "242000"]

Abstract:
This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein R A  is, for example, a group of the following formula (A-1): wherein ring A 1  is, for example, a cycloalkyl group which may be substituted,and R B  is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

Claim (Index 9):
The method according to  claim 3 ,\n wherein\n X a  is N, X b  is CH 2 , X c  is NH, and \n R B6  is a hydrogen atom.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 94.0
- Lexical Diversity: 1.76056
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15305587', '15313407', '13201536', '11363563', '14619980']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7996864723288936
- 35 USC 102 Novelty (BERT): 0.5738366504040303
- Combined Prediction Score: 0.7771014901364073
- Mean Citation Score: 313.52282600000007
- Max Citation Score: 484.2341
- Similarity Product: 380.30656805496216

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test